Axsome Therapeutics Inc. ( (AXSM) ) has released its Q1 earnings. Here is a breakdown of the information Axsome Therapeutics Inc. presented to its investors.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for central nervous system disorders, with a robust pipeline addressing various psychiatric and neurological conditions.
In the first quarter of 2025, Axsome Therapeutics reported a significant increase in net product revenue, reaching $121.5 million, a 62% growth compared to the previous year. The company highlighted the strong performance of its products AUVELITY and SUNOSI, and announced the FDA approval of SYMBRAVO for migraine treatment, with a commercial launch planned for June 2025.
Key financial metrics include AUVELITY’s net product sales of $96.2 million, an 80% increase year-over-year, and SUNOSI’s revenue of $25.2 million, a 17% growth. The company also reported a net loss of $59.4 million, an improvement from the previous year’s loss. Axsome continues to advance its late-stage neuroscience pipeline with several NDA submissions and clinical trials in progress.
Looking ahead, Axsome remains focused on expanding its product offerings and advancing its pipeline, with multiple NDA submissions and clinical trial initiations planned for 2025. The company aims to deliver transformative medicines to patients with serious CNS conditions, maintaining its momentum throughout the year.